Gender-specific determinants of asthma among U.S. adults

Rebecca Greenblatt, Omar Mansour, Edward Zhao, Michelle Ross and Blanca E Himes This email address is being protected from spambots. You need JavaScript enabled to view it.
 

Abstract

Background

Asthma, a chronic respiratory disease affecting over 18.7 million American adults, has marked disparities by gender, race/ethnicity and socioeconomic status. Our goal was to identify gender-specific demographic and socioeconomic determinants of asthma prevalence among U.S. adults using data from the Behavioral Risk Factors Surveillance System (BRFSS) and the National Health and Nutrition Examination Survey (NHANES).

Methods

Gender-specific regression analyses were performed to model the relationship between asthma prevalence with age, race/ethnicity, income, education level, smoking status, and body mass index (BMI), while taking into account the study designs.

Results

Based on BRFSS data from 1,003,894 respondents, weighted asthma prevalence was 6.2% in males and 10.6% in females. Asthma prevalence among grade 2 obese and grade 3 obese vs. not overweight or obese women was 2.5 and 3.5 times higher, respectively, while that in men was 1.7 and 2.4 times higher; asthma prevalence among current vs. never smoker women was 1.4 times higher, while that in men was 1.1 times higher. Similar results were obtained with NHANES data from 13,364 respondents: asthma prevalence among grade 2 obese and grade 3 obese vs. not overweight or obese respondents was 2.0 and 3.3 times higher for women, though there was no significant difference for men; asthma prevalence among current vs. never smokers was 1.8 times higher for women and not significantly different in men. Asthma prevalence by race/ethnicity and income levels did not differ considerably between men and women.

Conclusions

Our results underscore the importance of obesity and smoking as modifiable asthma risk factors that most strongly affect women.

Download PDF

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma Top story: United Action for Allergy and Asthma https://t.co/Bssbmnu3cF, see more https://t.co/CpGiFuOOYd
1hreplyretweetfavorite
Interasma RT @Aller_MD: Top story: United Action for Allergy and Asthma https://t.co/xdIbmmWD5j, see more https://t.co/jgCeENQuZt
3hreplyretweetfavorite
Interasma RT @ARIAGuideline: Emerging technologies for predictive medicine in chronic airway diseases... https://t.co/1uOqcIwQ1o
3hreplyretweetfavorite
Interasma RT @Aller_MD: “Global Market Study on AR: Immunotherapy Segment Projected to be the Fastest Growing Segment” https://t.co/FC1n10wV6o https:…
4hreplyretweetfavorite
Interasma RT @Aller_MD: Top story: The Myth of Drug Expiration Dates - ProPublica https://t.co/8bS0FafKTF, see more https://t.co/jgCeENQuZt
4hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma